We are building a new model for translational biomedical research enabled by new technologies and the changing landscape of healthcare.
“What will our healthcare experience look like in 2025 and how can we start to put the foundations of that experience into practice today?”
INGH is developing an integrated translational biomedical research model at the nexus of advances in –omics, clinical medicine, digital health, and artificial intelligence.
Health is more than the absence of disease but we lack fundamental understanding of what a “normal healthy” person is. How can we leverage repeat, longitudinal measures to map health and disease states? Are individual baselines or population averages more useful benchmarks of health? How do we quantify sleep, physical activity, neurological function, emotional wellbeing, social support, and other factors that comprise the “phenome”? How can we understand and predict transitions to disease if we don’t understand wellness at a deep level?
Care providers around the globe want the ability to deliver precision medicine to patients but lack the resources and capabilities of elite healthcare institutions. Patients want the healthcare system to deliver to their unique needs an preferences. How do we use artificial intelligence to interpret ultra-personalized patient information and deliver actionable clinical insights? How do we develop predictive models of disease that apply to individual patient health trajectories rather than population averages? How do we combine software and clinical measurement technologies to enable inexpensive “push button” precision medicine?
Clinical outcomes are the currency of medical practice and policy but establishing clinical evidence is limited to the relatively few elite academic and industry researchers. How do we enable patient groups to conduct rigorous clinical trials as easy as playing Pokemon Go? How do we enable care providers to run individual-level trials to guide personalized medicine? How do we build a scalable “learning healthcare system” that gets instantly gets smarter from every patient in the world that it cares for. How do we build systems that allow patients to define their own outcome endpoints (e.g., quantitative quality-of-life measures) beyond what FDA uses to approve drugs?